Unity Biotechnology, Inc.
UBX · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | -$0 | $1 | -$0 | -$0 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $3 | $3 | $3 | $3 |
| G&A Expenses | $4 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$10 | -$0 | $3 |
| Operating Expenses | $7 | -$3 | $6 | $10 |
| Operating Income | -$7 | -$7 | -$7 | -$7 |
| % Margin | – | -553.5% | – | – |
| Other Income/Exp. Net | -$0 | $2 | $0 | $2 |
| Pre-Tax Income | -$7 | -$8 | -$6 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$8 | -$6 | -$5 |
| % Margin | – | -635.5% | – | – |
| EPS | -0.43 | -0.5 | -0.38 | -0.31 |
| % Growth | 14% | -31.6% | -22.6% | – |
| EPS Diluted | -0.43 | -0.5 | -0.38 | -0.31 |
| Weighted Avg Shares Out | 17 | 17 | 17 | 17 |
| Weighted Avg Shares Out Dil | 17 | 17 | 17 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$8 | -$6 | -$5 |
| % Margin | – | -620.3% | – | – |